L

Lord Evans of Rainow (Con)

Speaking in the House of Lords on 9 November 2026

Debate

Health Bill

Contribution

My Lords, I apologise for interrupting the noble Lord; the House always enjoys hearing from him. I am speaking in an incredibly important and delicate debate. I thank all the noble Baronesses for tabling such amendments which address some of the most pressing challenges facing cancer patients and their families. Cancer is a disease for which time is so often the difference between life and death. Too many patients face delays in diagnosis, uncertainty over treatment and unacceptable inequalities in access to care. These amendments speak to a fundamental principle: improving cancer outcomes must remain a clear and measurable national priority. I welcome the amendments tabled by the noble Baroness, Lady Pidgeon, particularly Amendment 41, which seeks to ensure that cancer outcomes, including survival, remain a priority for the Secretary of State. Removing the existing statutory requirement risks weakening accountability at precisely the moment we need greater ambition. That ambition must extend to cancers with the poorest survival rates. I was encouraged to hear last week from the noble Baroness, Lady Merron, that the Government have commissioned an expert review into brain cancer research and that findings will be expected within just three months. This is welcome, but patients and families have heard promises before. What will be different this time? Can the Minister explain how the review will translate into tangible improvements in research funding, clinical trials and, ultimately, survival? The Government have also released a national cancer plan to support new clinical trials and increase research participation, coupled with an ambition to reduce clinical trial set-up times to 150 days by March 2026. These are positive steps, but they must be matched by the capacity to deliver them. Does the NHS have the workforce, infrastructure and resource necessary to turn this ambition into concrete results for patients? Research is essential, but so is timely treatment. What targeted funding do the Government further envisage for clinical trials? I will now address the amendment from the noble Baroness, Lady Pidgeon, which would strengthen patients’ rights to begin cancer treatment within 62 days of referral. This should be a reliable standard. Can the Minister explain why this target is not being met and what steps they are taking to do so? The urgency is particularly apparent in radiotherapy. As the noble Baroness, Lady Finlay, powerfully highlighted, radiotherapy is one of the worst performing cancer treatments. Only 62% of radiotherapy patients begin treatment in 62 days in comparison to 71% for surgery and 67% for chemotherapy—all fall short of the target of 85%. These figures should concern us all. Delays and geographical inequalities continue to undermine access to treatment. Can the Minister tell us whether the Government have begun to design a nationally co-ordinated programme addressing workforce shortages, equipment capacity and access to modern techniques?

More from Lord Evans of Rainow (Con)

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.